ImpactHealthcare5 MIN READ

DeepMind Spinout Isomorphic Labs Raises $5 Billion Series C to Industrialise AI Drug Discovery, Led by Greenoaks and Sequoia

Isomorphic Labs, the AI drug discovery company spun out of Google DeepMind, has raised a $5 billion Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz, Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund participating. The round, announced November 17, follows a $2.1 billion Series B in May.

By Prathista Lazar · Author19 November 2026New
DeepMind Spinout Isomorphic Labs Raises $5 Billion Series C to Industrialise AI Drug Discovery, Led by Greenoaks and Sequoia

Six months after one of the largest funding rounds in biotech history, Isomorphic Labs has raised more than twice as much again.

Isomorphic Labs, the London-based AI drug discovery company spun out of Google DeepMind, announced a $5 billion Series C funding round on Tuesday, November 17, according to Tech Startups. The round was co-led by Greenoaks and Sequoia Capital.

Andreessen Horowitz and Alphabet also participated, along with existing investors Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The company did not disclose its valuation. Earlier reports by Dealroom and others had said Isomorphic was in talks to raise about $5 billion at a valuation of about $50 billion.

The round follows a $2.1 billion Series B in May 2026.

The DeepMind connection

Isomorphic Labs was founded in 2021 by Demis Hassabis, the co-founder and chief executive of Google DeepMind, who also leads Isomorphic. It was spun out of DeepMind to apply AI to drug discovery, building on the success of AlphaFold, the AI system that predicts the three-dimensional structures of proteins.

AlphaFold transformed biological research by predicting the structures of hundreds of millions of proteins, a task that previously required years of laboratory work for each protein. Hassabis and DeepMind colleague John Jumper shared the 2024 Nobel Prize in Chemistry for the work.

How Isomorphic designs drugs

Isomorphic's IsoDDE drug design system proposes and refines candidate molecules computationally before they move into laboratory development, according to Tech Startups. By predicting how molecules interact with biological targets, the system aims to identify promising drug candidates faster and more cheaply than traditional methods.

The company has partnerships with Eli Lilly, Novartis and Johnson & Johnson, and runs its own drug programmes in oncology and immunology. It reports encouraging preclinical results, although these do not establish safety or effectiveness in patients.

Why drug discovery is ripe for AI

Developing a new drug typically takes more than a decade and costs billions of dollars, with most candidates failing in clinical trials. Much of the cost comes from the trial-and-error process of finding molecules that bind to the right targets, are safe and can be manufactured.

AI promises to accelerate this process by predicting molecular properties, simulating interactions and prioritising the most promising candidates. If successful, it could reduce costs, shorten timelines and increase the success rate of drug development, potentially bringing new treatments to patients faster.

The scale of the bet

A $5 billion round is extraordinary for a company that has not yet tested a drug in humans. Trending Topics described the round as a mega-round without a single drug tested in humans. Investors are betting that Isomorphic's technology will produce a pipeline of drugs that justify the investment, either through its own programmes or partnerships with pharmaceutical companies.

The size of the round also reflects the enormous capital being raised by AI companies across sectors, as investors seek exposure to what they see as transformative technology. The funding will allow Isomorphic to expand its computing infrastructure, laboratory capabilities and team, and to advance drug candidates into clinical trials.

The UK angle

The participation of the UK Sovereign AI Fund underscores the importance the British government places on Isomorphic as a national AI champion. London has become one of the world's leading centres for AI research, anchored by DeepMind, and the government has sought to support homegrown AI companies.

“Investors are now paying for the promise that AI can turn drug discovery from an art into an engineering discipline.”
— TIGI Healthcare Desk

Competition in AI drug discovery

Isomorphic competes with a growing number of AI drug discovery companies, including Recursion, Insilico Medicine, Xaira Therapeutics and others, as well as pharmaceutical companies building their own AI capabilities. Several AI-designed drugs have entered clinical trials, but none has yet been approved, leaving the field's ultimate impact unproven.

The industry's credibility will depend on demonstrating that AI-designed drugs succeed in clinical trials at higher rates or lower costs than traditionally discovered drugs.

532f8344-5b63-4313-acc0-5bfec5c2ae11.png

What it means for India

India's pharmaceutical industry, a global leader in generic drugs, is increasingly exploring AI for drug discovery and development. Indian companies and research institutions are using AI for target identification, molecule design and clinical trial optimisation. AI startups in India's life sciences sector have attracted investment, and global AI drug discovery companies could partner with Indian contract research organisations and manufacturers.

For Indian patients, faster and cheaper drug development could eventually mean more affordable treatments for diseases such as cancer and infectious diseases, although that remains a long-term prospect.

Partnerships with big pharma

Isomorphic's partnerships with Eli Lilly, Novartis and Johnson & Johnson give it access to the expertise, data and resources needed to take drug candidates through development. Such partnerships typically involve upfront payments, milestone payments as candidates progress and royalties on sales of approved drugs, providing revenue while the company advances its own pipeline.

For pharmaceutical companies, partnering with AI specialists offers a way to access cutting-edge technology without building it entirely in-house.

The role of computing power

AI drug discovery requires vast computing resources to train models and run simulations of molecular interactions. Part of Isomorphic's funding is likely to go towards computing infrastructure. The company's close relationship with Alphabet gives it access to expertise in AI research and infrastructure, an advantage over many competitors.

Critics caution that the history of drug development is filled with promising technologies that took far longer than expected to deliver results, and that biology remains far more complex than any model can fully capture. Supporters respond that AI's success in predicting protein structures has already changed research, and that applying similar approaches to drug design could produce similar breakthroughs.

The truth will become clearer as AI-designed drugs move through clinical trials over the coming years, providing the first hard evidence of whether the technology improves success rates.

The round also highlights how sovereign and strategic investors, from Temasek to the UK Sovereign AI Fund and Gulf-backed MGX, are increasingly participating in the largest AI deals, reflecting governments' desire to secure stakes in technologies they see as strategically important for their economies and national security.

Isomorphic did not say how it plans to allocate the new capital across its programmes.

What comes next

Isomorphic will use the funding to scale its platform and advance its drug programmes. The key milestone will be moving its first candidates into human trials. Investors and the pharmaceutical industry will watch closely for evidence that AI can deliver on its promise to transform medicine.

TagsIsomorphic LabsDemis HassabisGoogle DeepMindAI drug discoveryAlphaFoldIsoDDEGreenoaksSequoia CapitalAndreessen HorowitzAlphabetThrive CapitalTemasekUK Sovereign AI FundEli LillyNovartisJohnson & Johnsonbiotechpharmahealthcare AIinvestors

Reader reviews

Sign in to rate and review this article.
Loading reviews…